HORIZON THERAPEUTICS PLC (HZNP) Stock News
NASDAQ:HZNP - Nasdaq - IE00BQPVQZ61 - Common Stock - Currency: USD
HZNP Latest News, Press Relases and Analysis
3 Stocks to Buy Low Today With High Hopes for Tomorrow
Amgen, Canadian Solar, and Diana Shipping are three undervalued stocks with high potential for growth that can enhance portfolio returns.
Amgen Expects a 2024 Sales Jump, Sets Sights on Obesity Market
Amgen Inc. expects revenue to jump as much as 20% this year, as the purchase of Horizon Therapeutics Plc buoys the company while it works to become a major competitor in the weight-loss drug market.
Mentions: AMGN
Pfizer to close Seagen buyout this week as regulatory reviews complete (NYSE:PFE)
Pfizer (PFE) receives necessary approvals to complete its acquisition of Seagen (SGEN) this week as it addresses antitrust concerns. Read more here.
Tudor Investment opens new Seagen, AbbVie bets; exits Immersion, Lennox (NASDAQ:CME)
Monica Schipper Tudor Investment, the hedge fund founded by billionaire Paul Tudor Jones, started new positions in Seagen (NASDAQ:SGEN), with 340K shares,...
Microsoft-Activision Takeover Emboldens Merger Arb Traders to Boost Their Bets
Traders who bet on corporate mergers and acquisitions are boosting their wagers on a slew of proposed deals, after successful trades on transactions like Microsoft Corp.’s purchase of Activision Blizzard Inc. have left them with more money to invest.
Hedge Funds Won Big on Bets Amgen-Horizon Deal Would Go Through
Hedge funds Pentwater Capital Management, HBK Investments and Farallon Capital Management are reaping a windfall from bets that US regulators wouldn’t be able to stop Amgen Inc. from completing its $28 billion takeover of Horizon Therapeutics Plc.
Mentions: AMGN
Amgen completes $27.8B acquisition of Horizon Therapeutics (NASDAQ:AMGN)
Amgen completes $27.8 billion acquisition of Horizon Therapeutics, positioning itself as a leader in a wider range of diseases.
Mentions: AMGN
Rule 17(e) Announcement - Horizon Therapeutics plc
Amgen wins Irish approval for planned Horizon Therapeutics purchase
Amgen's $28 billion purchase of Horizon Therapeutics has received approval from the High Court of Ireland, clearing the final hurdle for the deal to close.
Mentions: AMGN
Rule 17(d) Announcement – Horizon Therapeutics plc
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics ticks higher amid Nasdaq delisting notice for sale to Amgen
Discover the latest news on Horizon Therapeutics as a delisting notice threatens its planned sale to Amgen, causing a slight uptick in stock.
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care Industry
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 List
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata
The 3 Most Undervalued Biotech Stocks to Buy in September 2023
While these undervalued biotech stocks have struggled of late, they could surprise investors and prove to be long-term winners.
Horizon Therapeutics stock ticks higher as Amgen end date extended until December
Horizon Therapeutics (HZNP) ticked up 0.4% after the end date for its planned $28 billion sale to Amgen was extended until December. The end date was extended to Dec
Mentions: AMGN
Horizon Therapeutics plc (“Horizon”) Rule 2.12 Announcement
